23andMe Holding Co. (ME)

NASDAQ: ME · IEX Real-Time Price · USD
0.532
+0.022 (4.23%)
At close: Mar 28, 2024, 4:00 PM
0.540
+0.008 (1.50%)
After-hours: Mar 28, 2024, 7:58 PM EDT

Company Description

23andMe Holding Co. operates as a consumer genetics testing company.

The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.

This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services.

The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development.

The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses.

The company was incorporated in 2006 and is headquartered in South San Francisco, California.

23andMe Holding Co.
23andMe Holding Co. logo
Country United States
Founded 2006
Industry Diagnostics & Research
Sector Healthcare
Employees 769
CEO Ms. Anne Wojcicki

Contact Details

Address:
349 Oyster Point Boulevard
South San Francisco, California 94080
United States
Phone (650) 938-6300
Website 23andme.com

Stock Details

Ticker Symbol ME
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001804591
CUSIP Number 90138Q108
ISIN Number US90138Q1085
Employer ID 87-1240344
SIC Code 2834

Key Executives

Name Position
Anne Wojcicki Co-Founder, Chief Executive Officer, President and Chair of the Board
Joseph Selsavage Interim Chief Financial Officer and Accounting Officer
Kathy L. Hibbs Esq., J.D. Chief Administrative Officer and Corporate Secretary
Guy Chayoun Vice President and Interim General Counsel
Katie Watson Vice President of Communications
Jonathan Ward Chief Marketing Officer
Reza Afkhami M.B.A. Chief Corporate Development Officer
Savita Pillai Vice President of People
Dr. Jennifer Low Head of Therapeutics Development
Kent Hillyer Vice President of Consumer Operations

Latest SEC Filings

Date Type Title
Mar 22, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 7, 2024 144 Filing
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 7, 2024 10-Q Quarterly Report
Feb 7, 2024 8-K Current Report
Jan 31, 2024 8-K Current Report
Jan 26, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 8, 2024 8-K Current Report
Dec 1, 2023 8-K/A [Amend] Current report